blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4398902

EP4398902 - COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF AMYLOID PEPTIDE INTERACTIONS WITH GLYCOSAMINOGLYCANS, METHODS OF TREATMENT, AND USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  14.06.2024
Database last updated on 30.10.2024
FormerThe international publication has been made
Status updated on  17.03.2023
Most recent event   Tooltip15.10.2024Amendment by applicant 
Applicant(s)For all designated states
Gismo Therapeutics, Inc.
A268 ASTECC-UK
Lexington, KY 40506-0286 / US
[2024/29]
Inventor(s)01 / GREGOR, Paul
NY 11414 / US
02 / KIM, Myung Hee
Lexington, KY 40503 / US
03 / MARRON, Brian
Ada, MI 449301 / US
 [2024/29]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[2024/29]
Application number, filing date22867944.506.09.2022
[2024/29]
WO2022US42597
Priority number, dateUS202163241148P07.09.2021         Original published format: US 202163241148 P
[2024/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2023038876
Date:16.03.2023
Language:EN
[2023/11]
Type: A1 Application with search report 
No.:EP4398902
Date:17.07.2024
Language:EN
The application published by WIPO in one of the EPO official languages on 16.03.2023 takes the place of the publication of the European patent application.
[2024/29]
Search report(s)International search report - published on:AU16.03.2023
ClassificationIPC:A61K31/4164, A61K31/4706, A61K31/4709, A61K31/517, A61K31/541, A61P25/28, C07D401/14, G01N33/53, G01N33/94, C07D215/42, C07D215/44, C07D221/08, C07D233/61, C07D239/94, C07D401/12
[2024/29]
CPC:
A61P25/28 (EP,AU); C07D401/14 (EP,AU); A61K45/06 (EP);
C07D215/42 (EP,AU); C07D215/44 (EP,AU); C07D221/08 (EP,AU);
C07D233/61 (EP,AU); C07D239/94 (EP,AU); C07D401/12 (EP,AU);
G01N33/5308 (AU); G01N33/94 (AU); G01N2333/4709 (AU);
G01N2400/40 (AU); G01N2470/10 (AU); G01N2500/02 (AU) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/29]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:VERBINDUNGEN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT INHIBITOREN VON AMYLOIDPEPTIDINTERAKTIONEN MIT GLYKOSAMINOGLYKANEN, BEHANDLUNGSVERFAHREN UND VERWENDUNG DAVON[2024/29]
English:COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF AMYLOID PEPTIDE INTERACTIONS WITH GLYCOSAMINOGLYCANS, METHODS OF TREATMENT, AND USE THEREOF[2024/29]
French:COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES INHIBITEURS D'INTERACTIONS DE PEPTIDE AMYLOÏDE AVEC DES GLYCOSAMINOGLYCANES, PROCÉDÉS DE TRAITEMENT ET UTILISATION DE CEUX-CI[2024/29]
Entry into regional phase03.04.2024National basic fee paid 
03.04.2024Search fee paid 
03.04.2024Designation fee(s) paid 
03.04.2024Examination fee paid 
Examination procedure03.04.2024Examination requested  [2024/29]
14.10.2024Amendment by applicant (claims and/or description)
Fees paidRenewal fee
27.09.2024Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO8905297  (SMITHKLINE BECKMAN INTERCREDIT [NL]);
 [X]WO9720822  (CIBA GEIGY AG [CH], et al);
 [X]WO0164645  (ORION CORP [FI], et al);
 [X]WO2004067513  (JUVANTIA PHARMA LTD OY [FI], et al);
 [A]WO2005000406  (NEUROCHEM INT LTD [CH], et al);
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.